Skip to main content
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest
  • facebook
  • twitter
  • linkedin
  • youtube
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest

A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection

  • Read more about A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection

A Multi-Site Clinical Evaluation of the LIAISON NES FLU A/B, RSV & COVID-19 Assay in Symptomatic Patients

  • Read more about A Multi-Site Clinical Evaluation of the LIAISON NES FLU A/B, RSV & COVID-19 Assay in Symptomatic Patients

Coherent Biopharma (Suzhou) Co., Ltd.

By jpalfreyman on Mon, 11/04/2024 - 09:54
  • Read more about Coherent Biopharma (Suzhou) Co., Ltd.

Validity and Reliability of the Mastitis Symptom Severity Assessment Methods (M-Score and BISSI) in Non-Lactational Mastitis

  • Read more about Validity and Reliability of the Mastitis Symptom Severity Assessment Methods (M-Score and BISSI) in Non-Lactational Mastitis

A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

  • Read more about A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

Clinical Study on the Immune Response Characteristics of Novel Coronavirus and Influenza Virus Infection

  • Read more about Clinical Study on the Immune Response Characteristics of Novel Coronavirus and Influenza Virus Infection

MxA-Guided Antiviral Treatment in Respiratory Viral Infections

  • Read more about MxA-Guided Antiviral Treatment in Respiratory Viral Infections

Analgesic Effect of M-TAPA and TAPB on Laparoscopic Cholesistectomy

  • Read more about Analgesic Effect of M-TAPA and TAPB on Laparoscopic Cholesistectomy

Silver Creek Pharmaceuticals

By jpalfreyman on Tue, 10/29/2024 - 10:00
  • Read more about Silver Creek Pharmaceuticals

Feasibility of a Well-being Promotion Self-management Intervention in Post-COVID-19 Patients

  • Read more about Feasibility of a Well-being Promotion Self-management Intervention in Post-COVID-19 Patients

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 37
  • Page 38
  • Page 39
  • Page 40
  • Current page 41
  • Page 42
  • Page 43
  • Page 44
  • Page 45
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Subscribe for updates from the Reagan-Udall Foundation for the FDA

Subscribe
(202) 849 - 2075
1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036
navigator@reaganudall.org
  • facebook
  • twitter
  • linkedin
  • youtube

© Reagan-Udall Foundation for the FDA
© Reagan-Udall Foundation for the FDA